Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Evaluating follow-up and complexity in cancer clinical trials (EFACCT): an eDelphi study of research professionals’ perspectives

(2020) Helene Markham Jones et al.   BMJ Open

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

(2020) Xiaoxiang Zhou et al.   BMC Medicine

Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors

(2020) Nicole A. Romanski et al.   EUROPEAN JOURNAL OF CANCER

Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort

(2020) Mateo Sanchis-Borja et al.   LUNG CANCER

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

(2020) Olga Nigro et al.   EUROPEAN JOURNAL OF CANCER

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

(2020) Alexander M. M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

(2019) V. Ellen Maher et al.   JOURNAL OF CLINICAL ONCOLOGY

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

(2019) Elena Verzoni et al.   Journal for ImmunoTherapy of Cancer

The promise of Immuno-oncology: implications for defining the value of cancer treatment

(2019) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy

(2019) Paolo Bossi et al.   Future Oncology

Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors

(2019) Filippo G. Dall’Olio et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

(2019) Puyuan Xing et al.   Journal for ImmunoTherapy of Cancer

Real-world evidence in safety assessment of new treatments

(2018) Karin E Smedby et al.   Lancet Haematology

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

(2018) Gita Thanarajasingam et al.   Lancet Haematology

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

(2018) Cheng Xu et al.   BMJ-British Medical Journal

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio

(2016) Alice Indini et al.   JOURNAL OF CLINICAL ONCOLOGY

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging Issues and Opportunities in Health Information Technology

(2016) Elizabeth A. Nardi et al.   Journal of the National Comprehensive Cancer Network

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care

(2016) Robert W. Carlson et al.   Journal of the National Comprehensive Cancer Network

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer

(2016) Tanya J. Williams et al.   JAMA Neurology

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY